PDF (Download) |
- St. John's Wort (Hypericum perforatum)
- Major Depression
- FasTrak
| Date: 11-25-2008 | HC# 110581-365 |
Re: Cochrane Review of St. John's Wort for Major Depression
Linde K, Berner MM, Kriston L. St John's wort for major depression. Cochrane Database of Systematic Reviews. 2008, Issue 4. Art. No.: CD000448. DOI: 10.1002/14651858.CD000448.pub3.
Depression
is typically treated with antidepressant medications. Although newer
antidepressants (SSRIs, serotonin selective reuptake inhibitors) are better
tolerated than older drugs, they still have many unwanted side effects.
Extracts of St John's wort (SJW, Hypericum perforatum) are prescribed in Germany
to treat depression. The purpose of this systematic review was to investigate
whether extracts of SJW are more effective than placebo and as effective as
standard antidepressants in the treatment of major depression; and whether they
have fewer adverse effects than standard antidepressant drugs. Similar reviews
have been published in the past. This review is an update, including the latest
published studies.
Only
randomized, double-blind studies were included in this review. Patients were
required to have major depression (meeting DSM-IV or ICD-10 criteria). Trials
in children (< 16 years) were not eligible. Studies evaluating combination
products were excluded. Trials using inappropriate synthetic drugs (e.g.
benzodiazepines) or a dosage of an antidepressant below the lower thresholds
recommended in current guidelines were excluded. Experimental and control
treatments had to be administered for a duration of at least four weeks. Trials
that only measured physiological parameters were excluded. Electronic databases
were searched through July 8, 2008. Reference lists were also searched. The
methodological quality of each trial was assessed by at least two independent
reviewers using Jadad scales. The report contains a table listing all of the
included trials and their Jadad scores. Data were extracted from the reports
and a meta-analysis was conducted. The main outcome measure for assessing
effectiveness was the response rate according to the HAMD, MADRS, or CGI scales.
The main outcome measure for adverse effects was the number of patients who
dropped out due to adverse effects.
A
total of 79 relevant studies were identified and 29 trials (with 5489 patients)
met the inclusion criteria, including 18 placebo-controlled studies and 17
active-controlled studies. The report includes a large table that describes all
of the included studies. The severity of depression was described as mild to moderate
in 19 trials, and moderate to severe in nine trials (one trial did not classify
severity). Eighteen trials were from German-speaking countries, four from the US, two from the UK,
and one each from Brazil, Canada, Denmark,
France and Sweden. Many
different SJW preparations were used in the trials. The range of daily doses
varied between 240 and 1800 mg, but most trials used 200-500 mg. The active
comparators were fluoxetine (6 trials, dosage 20-40 mg), sertraline (4 trials,
50-100 mg), imipramine (3 trials, dosage 100-150 mg), citalopram (1 trial, 20
mg), paroxetine (1 trial, 20-40 mg), maprotiline (1 trial, 75 mg), and amitriptyline
(1 trial, 75 mg). Treatment duration lasted four weeks (1 trial), six weeks (19
trials), seven weeks (1 trial), eight weeks (5 trials) or 12 weeks (4 trials).
The majority of studies were of high quality (Jadad score of 5 out of 5).
Efficacy
In
the placebo-controlled studies, patients receiving SJW were significantly more
likely to be treatment responders (responder rate ratio = 1.48; 95% CI: 1.23 –
1.77), but study results were highly heterogeneous. Variables affecting the
heterogeneity were baseline values (higher values had smaller effect size),
precision of the study (more precise studies had smaller effect size), and
country of origin (trials from German-speaking countries reported more positive
findings). Remission rates (HAMD score < 8 or < 7) were significantly
higher in patients receiving SJW than in those receiving placebo (ratio = 2.77;
95% CI: 1.80 – 4.26).
In
comparator trials, the results were statistically homogeneous. An analysis
based on the Hamilton Rating Scale for Depression (HAM-D) revealed no
statistical differences between the groups (RR = 1.01; 95% CI: 0.93 – 1.09). Analysis
based on the Clinical Global Impression Index (CGI) also found no relevant
differences (RR = 1.01; 95%CI: 0.94 – 1.09). Studies from German-speaking
countries reported findings that were slightly more favorable to SJW. However,
in the multivariable meta-regression analysis, trials with higher HAM-D baseline
values had less favorable results (P = 0.010), while country of origin and
precision had no significant influence in comparator trials.
Safety
The
number of patients dropping out for adverse effects (AEs) was similar among
patients receiving SJW and placebo (OR = 0.92; 95%CI: 0.45 – 1.88). Patients
treated with SJW were less likely to drop out of the study due to AEs than
patients treated with either older or newer (SSRIs) pharmaceuticals. More
patients treated with older pharmaceuticals had AEs than those taking SSRIs.
Overall
the findings support the use of SJW for treatment of major depression. It
appears that SJW is effective and safe.
The
authors of this 147 page report conclude:
"Patients
suffering from depressive symptoms who wish to use a St. John's wort product should consult a
health professional. Using a St. John's wort
extract might be justified, but important issues should be taken into account: St. John's wort products
available on the market vary to a great extent. The results of this review
apply only to the preparations tested in the studies included, and possibly to
extracts with similar characteristics. Side effects of St. John's wort extracts are usually minor
and uncommon. However, the effects of other drugs might be significantly
compromised."
In
previous versions of this Cochrane review (published in 1998 and 2005),
included trials were not restricted to patients with major depression, whereas
the inclusion criteria of the present study were restricted to patients with
major depression. This is not to say that SJW is ineffective in depressed
patients who are not classified as having major depression. Rather, this
restriction helped to decrease variability in the analysis.
A
limitation of this report is that the authors concluded that the results only
pertain to the preparations evaluated in the report. The authors state in a
table that the following preparations were used: Hypericum extract LI160,
HYP611, Calmigen, STW3-1, STW3-IV, STW3-VI, LoHyp-57, WS5572, WS5573, WS5570,
Iperisan, STEI 300, ZE117, D-0496, and Psychotonin forte. A table summarizing
the design of each study provides the SJW preparation that was used, together
with the manufacturer.
—Heather S. Oliff,
PhD |